Compare Cronos Group Inc (CRON) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs GeneDx Holdings Corp — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and Cronos Group Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and GeneDx Holdings Corp for 19 Days on average.
| CRON | WGS | |
|---|---|---|
Market Cap | $1.18B | $2.02B |
Volume | 968,037 | 734,640 |
Sector | Health | Health |
52-Week High | $3.55 | $167.51 |
52-Week Low | $2.30 | $34.51 |
Typical Hold Time | 22 Days | 19 Days |
Enterprise Value | $387.62M | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $9.45M in 2025 despite revenue growth to $146.59M, but recent quarters show earnings beats. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings. Recent news highlights investor day events and international expansion efforts.
The outlook is cautious; profitability improvements and cash flow generation are key catalysts, but high valuation multiples and negative net cash flow pose risks. Regulatory developments in cannabis markets and execution on growth targets will be critical for stock performance.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
